Immunotherapy, cancer and rheumatic diseases

Publication date: Available online 17 May 2019Source: Reumatología Clínica (English Edition)Author(s): Francisco Javier Nóvoa Medina, Delvys Rodríguez Abreu
Source: Reumatologia Clinica - Category: Rheumatology Source Type: research

Related Links:

This study reveals diverse T-cell clones in the blood of melanoma patients prior to immunotherapy, which may reflect the extent to which T cells are able to react against melanoma and potentially control melanoma progression. Therefore the T-cell clonality in the circulation may have predictive value for antitumor responses from checkpoint inhibition.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Condition:   Lung Cancer, Non-small Cell Intervention:   Device: VOC analysis Sponsor:   Hopital Foch Recruiting
Source: - Category: Research Source Type: clinical trials
Conditions:   Non-small Cell Lung Cancer;   IIIb/IIIc/IV;   First-line Treatment Interventions:   Biological: CIK cell;   Biological: IBI308;   Drug: Pemetrexed;   Drug: Gemcitabine;   Drug: Carboplatin Sponsor:   Tianjin Medical University Cancer Institute and Hospital Recruiting
Source: - Category: Research Source Type: clinical trials
Conditions:   Metastic Renal Cell Carcinoma;   Clear Cell Renal Cell Carcinoma;   Second-line Treatment Interventions:   Biological: SHR-1210;   Biological: CIK cells Sponsor:   Tianjin Medical University Cancer Institute and Hospital Recruiting
Source: - Category: Research Source Type: clinical trials
Seasoned Healthcare Entrepreneur strengthens Management Team OXFORD, England and HELSINKI, June 17, 2019 -- (Healthcare Sales &Marketing Network) -- Valo Therapeutics Limited (Valo Tx), a cancer immunotherapy company developing neoantigen-coated oncol... Biopharmaceuticals, Personnel Valo Therapeutics, PeptiCRAd
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
Immunotherapy using chimeric antigen receptor (CAR)-engineered lymphocytes has shown impressive results in leukemia. However, for solid tumors such as colorectal cancer (CRC), new preclinical models are needed that allow to test CAR-mediated cytotoxicity in a tissue-like environment. Here, we developed a platform to study CAR cell cytotoxicity against 3-dimensional (3D) patient-derived colon organoids. Luciferase-based measurement served as a quantitative read-out for target cell viability. Additionally, we set up a confocal live imaging protocol to monitor effector cell recruitment and cytolytic activity at a single organ...
Source: EMBO Journal - Category: Molecular Biology Authors: Tags: Cancer, Immunology, Methods & Resources Source Type: research
AbstractIntroductionComprehensive genetic cancer profiling using circulating tumor DNA has enabled the detection of National Comprehensive Cancer Network (NCCN) guideline-recommended somatic alterations from a single, non-invasive blood draw. However, reliably detecting somatic variants at low variant allele fractions (VAFs) remains a challenge for next-generation sequencing (NGS)-based tests. We have developed the single-molecule sequencing (SMSEQ) platform to address these challenges.MethodsThe OncoLBx assay utilizes the SMSEQ platform to optimize cell-free DNA extraction and library preparation with variant type-specifi...
Source: Molecular Diagnosis and Therapy - Category: Molecular Biology Source Type: research
Josep Piulats Uveal melanoma is considered a rare disease but it is the most common intraocular malignancy in adults. Local treatments are effective, but the systemic recurrence rate is unacceptably high. Moreover, once metastasis have developed the prognosis is poor, with a 5-year survival rate of less than 5%, and systemic therapies, including immunotherapy, have rendered poor results. The tumour biology is complex, but angiogenesis is a highly important pathway in these tumours. Vasculogenic mimicry, the ability of melanomas to generate vascular channels independently of endothelial cells, could play an important ro...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
AbstractSmall cell lung cancer (SCLC) is a highly lethal subtype of lung cancer that has seen few therapeutic advances, despite ongoing concerted efforts. Immunotherapy has been an effective option in other carcinogen-related cancers and has shown modest activity in SCLC. Monotherapy with the anti-PD-1 antibody nivolumab in patients with at least two prior lines of therapy was associated with a response rate of 11.9% and a median duration of response of 17.9  months, leading to accelerated approval by the Food and Drug Administration (FDA) as third-line therapy for SCLC. Second-line checkpoint inhibitors have not perf...
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
Source: OncoImmunology - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Immunotherapy | Rheumatology